MONT-SAINT-GUIBERT, Belgium — Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of its Allo Chassis™—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cell primary cells. These innovative cell lines represent a substantial leap forward in cell line development, effectively reducing both timelines and costs. Leveraging Cellistic’s extensive expertise in iPSCs, including in the development of T-cell based treatments, the Allo Chassis™ cell lines set a new standard in the cell therapy market with their unprecedented technology, developed in accordance with current Good Manufacturing Practice (cGMP) standards. [Read more…]
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials
AUSTIN, Texas — Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Fertilo, to enable the launch of the first US-based Phase 3 clinical trial for an induced pluripotent stem cell (iPSC)-based therapy. This groundbreaking milestone highlights the potential of iPSC technology to address critical unmet needs in reproductive medicine. [Read more…]
Ncardia launches Ncyte® Heart in a Box
LEIDEN, THE NETHERLANDS, February 6, 2025 – Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery.
The Ncyte® Heart in a Box system is derived from hiPSC and integrates three essential cardiac cell types: ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts. Together, these high-purity components form a physiologically relevant microtissue that replicates the complexity and functionality of the human heart. [Read more…]
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product
February 5, 2025, Palo Alto, CA – Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product. [Read more…]
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
Collaboration leverages Ginkgo’s cell engineering and screening platform to enhance the potency and persistence of Universal Cells’ iPSC-derived immune cell therapeutics
BOSTON, Jan. 13, 2025 – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo’s capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 79
- Next Page »